349 related articles for article (PubMed ID: 15623652)
1. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.
Sprague JE; Peng Y; Sun X; Weisman GR; Wong EH; Achilefu S; Anderson CJ
Clin Cancer Res; 2004 Dec; 10(24):8674-82. PubMed ID: 15623652
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
[TBL] [Abstract][Full Text] [Related]
3. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.
Guo Y; Ferdani R; Anderson CJ
Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.
Lewis JS; Srinivasan A; Schmidt MA; Anderson CJ
Nucl Med Biol; 1999 Apr; 26(3):267-73. PubMed ID: 10363797
[TBL] [Abstract][Full Text] [Related]
5. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.
Wadas TJ; Eiblmaier M; Zheleznyak A; Sherman CD; Ferdani R; Liang K; Achilefu S; Anderson CJ
J Nucl Med; 2008 Nov; 49(11):1819-27. PubMed ID: 18927338
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.
Nedrow JR; White AG; Modi J; Nguyen K; Chang AJ; Anderson CJ
Mol Imaging; 2014; 13():. PubMed ID: 25060207
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.
Boswell CA; Sun X; Niu W; Weisman GR; Wong EH; Rheingold AL; Anderson CJ
J Med Chem; 2004 Mar; 47(6):1465-74. PubMed ID: 14998334
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents.
Sprague JE; Peng Y; Fiamengo AL; Woodin KS; Southwick EA; Weisman GR; Wong EH; Golen JA; Rheingold AL; Anderson CJ
J Med Chem; 2007 May; 50(10):2527-35. PubMed ID: 17458949
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.
Lewis JS; Lewis MR; Cutler PD; Srinivasan A; Schmidt MA; Schwarz SW; Morris MM; Miller JP; Anderson CJ
Clin Cancer Res; 1999 Nov; 5(11):3608-16. PubMed ID: 10589778
[TBL] [Abstract][Full Text] [Related]
10. Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line.
Eiblmaier M; Andrews R; Laforest R; Rogers BE; Anderson CJ
J Nucl Med; 2007 Aug; 48(8):1390-6. PubMed ID: 17631550
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.
Nguyen K; Parry JJ; Rogers BE; Anderson CJ
Nucl Med Biol; 2012 Feb; 39(2):187-97. PubMed ID: 22056254
[TBL] [Abstract][Full Text] [Related]
12. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.
Sun X; Wuest M; Weisman GR; Wong EH; Reed DP; Boswell CA; Motekaitis R; Martell AE; Welch MJ; Anderson CJ
J Med Chem; 2002 Jan; 45(2):469-77. PubMed ID: 11784151
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
14. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
Lewis JS; Laforest R; Lewis MR; Anderson CJ
Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
[TBL] [Abstract][Full Text] [Related]
15. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
16. 64Cu-labeled somatostatin analogues conjugated with cross-bridged phosphonate-based chelators via strain-promoted click chemistry for PET imaging: in silico through in vivo studies.
Cai Z; Ouyang Q; Zeng D; Nguyen KN; Modi J; Wang L; White AG; Rogers BE; Xie XQ; Anderson CJ
J Med Chem; 2014 Jul; 57(14):6019-29. PubMed ID: 24983404
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide.
Sprague JE; Kitaura H; Zou W; Ye Y; Achilefu S; Weilbaecher KN; Teitelbaum SL; Anderson CJ
J Nucl Med; 2007 Feb; 48(2):311-8. PubMed ID: 17268030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
